Abemaciclib

Major

Abemaciclib Omaveloxolone Skyclarys Explained Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Abemaciclib Pacritinib Vonjo® Explained Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Abemaciclib Palbociclib Ibrance Explained Increased exposure to CYP3A substrates with a narrow therapeutic index Details Abemaciclib Phenobarbital Fidoquel Explained Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Abemaciclib Phenytoin Dilantin Explained Decreased abemaciclib plasma concentration Details Abemaciclib Pimozide Explained Increased pimozide exposure and an increased risk of pimozide-related adverse reactions Details Abemaciclib Primidone Mysoline Explained Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Abemaciclib Ranolazine Aspruzyo Explained Increased exposure of CYP3A4 substrate Details Abemaciclib Relacorilant Lifyorli Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4-substrate-related adverse reactions Details Abemaciclib Repotrectinib Augtyro Explained Reduced CYP3A4 substrates exposure and reduced efficacy of CYP3A4 substrates Details Abemaciclib Ribociclib Kisqali Explained Increased exposure of CYP3A4 substrate and an increased risk of CYP3A4 substrate-related adverse reactions Details Abemaciclib Rifampin Rifadin Explained Decreased abemaciclib plasma concentration Details Abemaciclib Ritlecitinib Litfulo Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Abemaciclib Rotavirus Vaccine, Live Explained An increased risk of infection by the live vaccine Details Abemaciclib Selpercatinib Retevmo Explained Increased substrate exposure and an increased risk for adverse effects Details Abemaciclib Sevabertinib Hyrnuo Explained Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Abemaciclib Sotorasib Lumakras Explained Reduced exposure to CYP3A substrate and an increased risk of therapeutic failure Details Abemaciclib St John's Wort Explained Decreased abemaciclib plasma concentration Details Abemaciclib Suzetrigine Journavx Explained Reduced sensitive CYP3A substrate with NTI exposure and reduced efficacy of sensitive CYP3A substrate with NTI Details Abemaciclib Taurursodiol Explained Decreased exposure of the CYP3A4 substrate Details Abemaciclib Tazemetostat Tazverik Explained Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Abemaciclib Tizanidine Explained Increased tiZANidine exposure and an increased risk of tiZANidine-related hypotension, bradycardia or increased drowsiness Details Abemaciclib Tocilizumab Actemra Explained Reduced CYP3A4 substrate with NTI exposure and reduced efficacy of CYP3A4 substrate with NTI Details Abemaciclib Tovorafenib Ojemda Explained Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Abemaciclib Treosulfan Grafapex Explained Increased CYP3A4 substrate exposure and an increased risk of CYP3A4 substrate-related adverse and serious life-threatening toxicit... Details Abemaciclib Trofinetide Daybue Explained Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related toxicities Details Abemaciclib Tucatinib Tukysa Explained Increased exposure to CYP3A substrate and risk of toxicity Details Abemaciclib Vonoprazan Voquezna Explained Increased CYP3A substrates exposure Details Abemaciclib Vorasidenib Voranigo Explained Reduced CYP3A substrate with NTI exposure and reduced efficacy of CYP3A substrate with NTI Details Abemaciclib Voxelotor Oxbryta Explained Increased exposure of sensitive CYP3A4 substrates Details Abemaciclib Ketoconazole Topical Extina® Foam Increased abemaciclib exposure Details Abemaciclib Lanreotide Injection Somatuline Altered exposure to CYP3A4 substrate Details Abemaciclib Lenacapavir Injection Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Abemaciclib Lenacapavir Oral Sunlenca Increased sensitive CYP3A substrate exposure and an increased risk of sensitive CYP3A substrate-mediated adverse reactions Details Abemaciclib Octreotide Injection Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details